D
Daniel P. Bondeson
Researcher at Yale University
Publications - 10
Citations - 2045
Daniel P. Bondeson is an academic researcher from Yale University. The author has contributed to research in topics: Protein degradation & Ubiquitin ligase. The author has an hindex of 7, co-authored 10 publications receiving 1360 citations. Previous affiliations of Daniel P. Bondeson include Mayo Clinic & Broad Institute.
Papers
More filters
Journal ArticleDOI
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson,Alina Mares,Ian Edward David Smith,Ko Eunhwa,Sebastien Andre Campos,Afjal Hussain Miah,Katie E Mulholland,Natasha Routly,Dennis L. Buckley,Jeffrey L. Gustafson,Nico Zinn,Paola Grandi,Satoko Shimamura,Giovanna Bergamini,Maria Faelth-Savitski,Marcus Bantscheff,Carly S. Cox,Deborah A. Gordon,Ryan R. Willard,John J. Flanagan,Linda N. Casillas,Bartholomew J. Votta,Willem den Besten,Kristoffer Famm,Laurens Kruidenier,Paul S. Carter,John D. Harling,Ian Churcher,Craig M. Crews +28 more
TL;DR: Major improvements to the proteolysis targeting chimeras (PROTACs) method are described, a chemical knockdown strategy in which a heterobifunctional molecule recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degradation.
Journal ArticleDOI
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson,Blake E. Smith,George M. Burslem,Alexandru D. Buhimschi,John Hines,Saul Jaime-Figueroa,Jing Wang,Brian D. Hamman,Alexey Ishchenko,Craig M. Crews +9 more
TL;DR: A previously understudied benefit of small molecule proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degradation is reported.
Journal ArticleDOI
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem,Blake E. Smith,Ashton C. Lai,Saul Jaime-Figueroa,Daniel McQuaid,Daniel P. Bondeson,Momar Toure,Hanqing Dong,Yimin Qian,Jing Wang,Andrew P. Crew,John Hines,Craig M. Crews +12 more
TL;DR: The ability to target receptor tyrosine kinases for degradation using the PROTAC technology is demonstrated and the advantages of this degradation-based approach are outlined.
Journal ArticleDOI
Targeted Protein Degradation by Small Molecules
TL;DR: Recent advances in the use of small molecules to degrade proteins in a selective manner are reviewed to highlight all-small-molecule techniques with direct clinical application and describe techniques that may find broader acceptance in the biomedical research community that require little or no synthetic chemistry.
Journal ArticleDOI
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
George M. Burslem,Anna Reister Schultz,Daniel P. Bondeson,Christopher A. Eide,Christopher A. Eide,Samantha L. Savage Stevens,Brian J. Druker,Brian J. Druker,Craig M. Crews +8 more
TL;DR: Together, these findings suggest that combined BCR-ABL1 kinase inhibition and protein degradation may represent a strategy to address B CR-ABl1-dependent drug resistance, and warrants further investigation into the eradication of persistent leukemic stem cells, which rely on neither the presence nor the activity of the BCR/F3 protein for survival.